ENDRA Life Sciences appoints new CEO, raises $8M, reduces annual OpEx by $3.1M

ENDRA Life Sciences Inc.

New acting CEO Alexander Tokman appointed; CFO Richard Jacroux and Regulatory head Ziad Rouag join.
Gross proceeds of $8.0M from public offering of common stock and warrants.
Annualized operating expenses reduced by $3.1M (26%) vs prior year; Q2 OpEx $2.2M.
Cash and cash equivalents $6.4M at June 30, 2024.
Advanced FDA regulatory process; initiated new pilot trials at two North American sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.